Canadian CANNAINVESTOR Magazine October 2017 - Page 98

ABcann Releases High Level CBD Product and Launches Initial Oils Strategy August 28, 2017 – Ottawa, ON – ABcann Global Corporation (TSX-V:ABCN) (“ABcann” or the “Company”) is pleased to announce the release of one of Canada's highest legal CBD:THC (cannabidol:tetrahydrocannabinol) ratio products available on the market by its wholly-owned subsidiary, ABcann Medicinals Inc. The release of CBD-Med is part of the Company's strategy to provide a diverse range of products as it formally initiates the process to begin selling oils. CBD-Med has a ratio of 27.6:1 (18.5% CBD to 0.67% THC), putting the product into a very select class as one of Canada's highest CBD products under Health Canada regulations. In addition to formally offering this product line to its patient base, ABcann is anticipating being able to sell oils in October as it continues to diversify its product lines. Products that ABcann will have available for patients are expected to include a 1-1 THC/CBD drop, a high THC dropper and a high CBD dropper. This new high CBD product is in addition to ABcann's current high CBD products: NC:Med - 18.9:1 (18.9% CBD to 1% THC) and DC:Med - 15.4:1 (15.4% CBD to 1% THC). ABcann will be able to release additional product details shortly regarding the formulations of capsules and soft gels. "The development of these products is in line with ABcann's corporate strategy as a premium product provider of organic, pesticide free cannabis," says Ken Clement, Executive Chairman of ABcann. "As the Company continues to scale production capacity, our product line will expand as we strive to increase shareholder value through capturing a larger market share of the current global medical markets." "ABcann will continue to advance our core businesses and subsidiaries as production capacity continues to increase through our aggressive construction and expansion plans," says Aaron Keay, Chief Executive